Individualizing fetal hemoglobin augmenting therapy for β-type hemoglobinopathies patients

Area of Science:

• Pharmacogenomics
• Genetics
• Hematology

Background:

• Individual genetic makeup influences drug response and tolerance.
• Pharmacogenomics aims to map genomic profiles to drug responses.
• Its application varies across medical disciplines.

Purpose of the Study:

• To update on pharmacogenomics in β-type hemoglobinopathies therapeutics.
• To discuss future challenges in applying pharmacogenomics for these disorders.
• To relate pharmacogenomics to current treatment modalities.

Main Methods:

• Review of experimental evidence on genetic variations and drug response.
• Analysis of modifier genes outside the β-globin gene cluster.
• Focus on fetal hemoglobin level increases as a response indicator.

Main Results:

• Genetic variations within and outside the β-globin gene cluster affect hydroxyurea response.
• Modifier genes outside the cluster are significantly associated with treatment outcomes.
• Increased fetal hemoglobin levels indicate treatment response.

Conclusions:

• Pharmacogenomics offers personalized therapeutic strategies for β-type hemoglobinopathies.
• Understanding genetic variants is crucial for optimizing hydroxyurea treatment.
• Further research is needed to address challenges in pharmacogenomic applications.